Hamburg, Germany, 15 February 2022:
Evotec SE (FSE: EVT; MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has made an equity investment in IMIDomics, Inc., a privately held global biotechnology company focused on the discovery and development of new targets and medicines for the treatment of patients with immune-mediated inflammatory diseases ("IMIDs"). 

IMIDs affect nearly one in ten people – limiting quality of life and creating significant challenges to physical and mental well-being. The complexity of these diseases means even getting a diagnosis can be a long-term struggle for patients, and then finding a treatment that works can be a frustrating, time-consuming trial and error process.

“Evotec and IMIDomics are perfectly aligned on their goal to leverage data to discover and develop precise-acting, effective medicines of the future,” said Dr Werner Lanthaler, Chief Executive Officer of Evotec. “By joining IMIDomics as a minority shareholder, we are excited to further grow our EVOequity portfolio of highly promising companies with complementary technologies and assets.”

In conjunction with the investment, an Evotec representative will join the IMIDomics board of directors. No financial details were disclosed.

For further information, please follow this link to the press release from IMIDomics.